- Home
- NYT vs ROIV Comparison
NYT vs ROIV Comparison
Compare NYT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- ROIV
- Stock Information
- Founded
- NYT 1851
- ROIV 2014
- Country
- NYT United States
- ROIV United Kingdom
- Employees
- NYT N/A
- ROIV N/A
- Industry
- NYT Newspapers/Magazines
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- NYT Consumer Discretionary
- ROIV Health Care
- Exchange
- NYT Nasdaq
- ROIV Nasdaq
- Market Cap
- NYT 8.6B
- ROIV 7.8B
- IPO Year
- NYT N/A
- ROIV N/A
- Fundamental
- Price
- NYT $54.48
- ROIV $11.45
- Analyst Decision
- NYT Buy
- ROIV Buy
- Analyst Count
- NYT 5
- ROIV 4
- Target Price
- NYT $56.40
- ROIV $17.50
- AVG Volume (30 Days)
- NYT 1.4M
- ROIV 6.1M
- Earning Date
- NYT 08-06-2025
- ROIV 08-07-2025
- Dividend Yield
- NYT 1.32%
- ROIV N/A
- EPS Growth
- NYT 21.26
- ROIV N/A
- EPS
- NYT 1.83
- ROIV N/A
- Revenue
- NYT $2,600,814,000.00
- ROIV $29,053,000.00
- Revenue This Year
- NYT $8.84
- ROIV $2.64
- Revenue Next Year
- NYT $5.89
- ROIV $378.09
- P/E Ratio
- NYT $29.77
- ROIV N/A
- Revenue Growth
- NYT 6.90
- ROIV N/A
- 52 Week Low
- NYT $44.83
- ROIV $8.73
- 52 Week High
- NYT $58.16
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- NYT 47.36
- ROIV 57.83
- Support Level
- NYT $52.81
- ROIV $10.89
- Resistance Level
- NYT $56.27
- ROIV $11.79
- Average True Range (ATR)
- NYT 0.83
- ROIV 0.35
- MACD
- NYT -0.38
- ROIV 0.01
- Stochastic Oscillator
- NYT 38.22
- ROIV 62.57
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.